Diabetes & Vascular Disease Research is a leading academic journal dedicated to advancing the understanding and treatment of cardiovascular and metabolic diseases, particularly diabetes. Published by SAGE Publications Ltd in the United Kingdom, this journal serves as a key resource for researchers, clinicians, and students seeking to explore the intricate relationship between diabetes and vascular health. With an impressive Impact Factor and ranked in the Q2 quartile in prominent categories such as Cardiology, Endocrinology, and Internal Medicine, the journal provides a platform for high-quality, peer-reviewed research. Covering a broad range of topics from pathophysiology to therapeutic innovations, Diabetes & Vascular Disease Research plays a vital role in shaping contemporary discourse in the field. With contributions from leading experts and a commitment to disseminating valuable findings, this journal is a must-read for anyone involved in the fight against vascular complications arising from diabetes.

Circulation-Cardiovascular Interventions, published by LIPPINCOTT WILLIAMS & WILKINS, is a premier journal in the field of cardiology and cardiovascular medicine, recognized for its commitment to advancing the understanding and treatment of cardiovascular diseases. With a robust Impact Factor and ranking in the top 10% of its category, it serves as an essential resource for researchers, clinicians, and students seeking to stay at the forefront of cardiovascular intervention developments. This esteemed journal covers a range of topics, including innovative therapeutic strategies, cutting-edge clinical trials, and comprehensive reviews that inform clinical practice and influence guidelines. Since its inception in 2008, and extending through 2024, Circulation-Cardiovascular Interventions has published pivotal research that shapes the landscape of cardiovascular care in the United States and beyond. Its commitment to high-quality publications makes it an invaluable platform for sharing knowledge and fostering collaboration within the global medical community.

COR ET VASA is a prominent peer-reviewed journal in the field of cardiology and cardiovascular medicine, published by the Czech Society of Cardiology and Czech Society of Cardiovascular Surgery. Established in 1961, and continuing its legacy from 2006 to 2024, this journal serves as an essential platform for disseminating significant research findings, clinical studies, and innovative treatments in cardiovascular health. While currently positioned in the Q4 quartile, the journal aims to enhance its impact by fostering knowledge sharing among researchers, clinicians, and students alike. The journal, with its publication in Czech Republic, provides a unique perspective to the European cardiovascular community, allowing for invaluable insights and discourse. Researchers are encouraged to submit their manuscripts and contribute to the growing body of knowledge in this critical area, although it should be noted that COR ET VASA does not offer open access options at this time. As the field of cardiovascular medicine evolves, COR ET VASA remains committed to addressing the latest challenges and advancements, nurturing a rich dialogue within the community.

Cardiovascular Therapeutics is a renowned Open Access journal, published by WILEY-HINDAWI, that has been at the forefront of advancing knowledge in the field of cardiology and cardiovascular medicine since its establishment. With a strong commitment to disseminating high-quality research, the journal has successfully positioned itself within the Q2 quartile in multiple categories, including Cardiology and Cardiovascular Medicine, Medicine (miscellaneous), and Pharmacology. The journal is indexed in Scopus, achieving impressive rankings, such as #95 out of 387 in Cardiology, and #87 out of 272 in Medical Pharmacology. Situated in the United Kingdom, Cardiovascular Therapeutics embraces an Open Access model since 2019, ensuring that groundbreaking research is accessible to researchers, practitioners, and students across the globe. The journal is dedicated to publishing original research articles, reviews, and clinical studies that contribute to the understanding and treatment of cardiovascular diseases, making it an essential resource for those invested in improving patient outcomes and advancing therapeutic strategies in this vital area of medicine.

BMC Cardiovascular Disorders is a premier open access journal dedicated to the field of cardiology and cardiovascular medicine, published by BMC, a leading publisher in the scientific community. Since its inception in 2001, this journal has provided a platform for high-quality research, showcasing innovative studies and critical reviews that contribute to the understanding and management of cardiovascular diseases. With an impressive impact factor and a rank in the Q2 category for 2023 within its field, BMC Cardiovascular Disorders stands at the forefront of cardiovascular research, enabling accessibility to a wealth of information that fosters collaboration and advancements in patient care. The journal's commitment to open access ensures that research is widely disseminated and easily accessible to researchers, practitioners, and students globally, enhancing the dialogue around cardiovascular health and disease prevention. Located in the United Kingdom, BMC Cardiovascular Disorders consistently aims to promote excellence in the study and treatment of cardiovascular conditions, encouraging the exchange of knowledge that ultimately benefits public health.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, published by Lippincott Williams & Wilkins, is a leading journal in the field of cardiovascular medicine, dedicated to the advancement of research surrounding arterial diseases, thrombosis, and vascular biology. With an impressive impact factor indicative of its reach and influence, this journal occupies a prominent position in the Q1 category of cardiology, ranking 13th out of 387 in its field according to Scopus, placing it within the top 96th percentile among cardiovascular research journals. Since its inception in 1990, ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY has been pivotal in disseminating cutting-edge research that drives innovation and education in cardiovascular health. Although it does not operate under an open access model, the journal is a vital resource for researchers, clinicians, and students looking for high-quality, peer-reviewed articles that contribute to the understanding and treatment of cardiovascular and vascular disorders. Its commitment to rigorous scientific standards and its focus on impactful findings make it an essential publication for anyone dedicated to the field.

Vascular Health and Risk Management is a leading peer-reviewed journal published by DOVE MEDICAL PRESS LTD, focusing on the critical areas of cardiology, endocrinology, and public health. With an impact factor that reflects its significance within the scientific community, this Open Access journal, established in 2005, has been committed to enhancing knowledge on the interplay between vascular health and various risk factors affecting patient outcomes. The journal is proudly based in New Zealand and is indexed across multiple categories, maintaining a prominent Q2 ranking in cardiology, endocrinology, diabetes, and several other medical disciplines as of 2023. By providing a platform for innovative research and comprehensive reviews, Vascular Health and Risk Management seeks to foster collaboration among healthcare professionals, enhance clinical practices, and ultimately improve patient care through rigorous scientific inquiry and disseminated knowledge. Researchers, professionals, and students will find invaluable insights that inform their work and advance the understanding of vascular-related health issues.

CARDIOLOGY, published by KARGER, is a renowned scholarly journal dedicated to the advancement of research in the fields of cardiology and cardiovascular medicine. Since its inception in 1937, the journal has consistently provided a platform for high-quality, peer-reviewed articles that contribute to the understanding and treatment of heart and vascular diseases. With an impressive convergence through 2024, CARDIOLOGY holds a respectable Q2 ranking in both the Cardiology and Cardiovascular Medicine and Pharmacology (medical) categories, placing it within the 53rd and 45th percentiles of respective Scopus ranks. Based in Switzerland, the journal serves as an essential resource for researchers and practitioners aiming to stay abreast of cutting-edge developments and evidence-based practices in cardiovascular health. While it currently does not offer open access options, its commitment to rigorous scientific standards solidifies its significance within the academic community. We invite readers to explore the latest research findings and contribute to this vital field through publications in CARDIOLOGY.

Current Atherosclerosis Reports, published by CURRENT MEDICINE GROUP, is a leading scientific journal in the field of Cardiology and Cardiovascular Medicine, boasting an impressive Q1 ranking in its category as of 2023. This esteemed journal, with an ISSN of 1523-3804 and an E-ISSN of 1534-6242, has been a cornerstone of cardiovascular research since its inception in 1999, continuing to publish cutting-edge studies through 2024. With unparalleled insights into the mechanisms, prevention, and treatment of atherosclerosis, it serves as an essential resource for researchers, healthcare professionals, and students alike. Although not an open-access journal, it is highly regarded within the academic community, highlighted by its Scopus rank of #54 out of 387 in its field, placing it in the 86th percentile. The journal's commitment to advancing knowledge in cardiovascular health underscores its integral role in guiding clinical practices and influencing future research directions.

IJC Heart & Vasculature is a premier open-access journal published by Elsevier Ireland Ltd, dedicated to advancing research in the fields of cardiology and cardiovascular medicine. Since its inception in 2013, this journal has established itself as a valuable resource for clinicians, researchers, and students keen on exploring the latest developments in heart and vascular health. With an impressive impact factor and ranked within Q2 in its category (2023), IJC Heart & Vasculature has achieved a significant Scopus rank of #125 out of 387, placing it in the 67th percentile of cardiology journals. The journal not only emphasizes high-quality research but also promotes innovative studies that can shape clinical practices and improve patient outcomes. Researchers and professionals can access a plethora of peer-reviewed articles, original research, and comprehensive reviews that unravel the complexities of cardiovascular science. With a commitment to fostering open and impactful dialogue in the field, IJC Heart & Vasculature is poised to be an essential platform for knowledge exchange in the evolving landscape of cardiovascular research.